Pharmaceutical group Dis-chem saw revenue growth of more than 12% to R11.6 billion for the 22 weeks to 2 February.
Dis-Chem released an update to shareholders on Wednesday and reported that stores in convenience centres are still outperforming those in more crowded malls due to Covid-19. A change in sales mix has put pressure on profit margins, which remain below pre-pandemic levels, the group said.
“Healthcare, vitamins and chronic drug sales reported remarkable growth as consumers continue to focus on preventative healthcare,” said Dis-Chem CEO Ivan Saltzman
Dis-Chem has two operating segments – retail and wholesale. Retail revenue increased by 10.3% to R10.4 billion, while wholesale revenue grew by 20% to R8.6 billion.
Business Insider SA